Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis

OBJECTIVE: The phosphatidylinositol 3-kinase (PI3K) signaling pathway is a promising treatment target for patients with breast cancer (BC). Our study aimed to evaluate the most effective and safe PI3K inhibitor for patients with BC, especially in PIK3CA mutation. METHODS: Electronics databases were...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shu, Liu, Mingyue, Lian, Siheng, Liu, Naiming, Zhang, Guibin, Zhao, Qingchun, Zhang, Yingshi, Jian, Lingyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739049/
https://www.ncbi.nlm.nih.gov/pubmed/33376736
http://dx.doi.org/10.1155/2020/7451576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739049/
https://www.ncbi.nlm.nih.gov/pubmed/33376736
http://dx.doi.org/10.1155/2020/7451576

Ejemplares similares